Next generation bone tissue engineering: non-viral miR-133a inhib.pdf (1.26 MB)
0/0

Next generation bone tissue engineering: non-viral miR-133a inhibition using collagen-nanohydroxyapatite scaffolds rapidly enhances osteogenesis.

Download (1.26 MB)
journal contribution
posted on 22.11.2019 by Irene Mencía Castaño, Caroline M. Curtin, Garry P. Duffy, Fergal O'Brien

Bone grafts are the second most transplanted materials worldwide at a global cost to healthcare systems valued over $30 billion every year. The influence of microRNAs in the regenerative capacity of stem cells offers vast therapeutic potential towards bone grafting; however their efficient delivery to the target site remains a major challenge. This study describes how the functionalisation of porous collagen-nanohydroxyapatite (nHA) scaffolds with miR-133a inhibiting complexes, delivered using non-viral nHA particles, enhanced human mesenchymal stem cell-mediated osteogenesis through the novel focus on a key activator of osteogenesis, Runx2. This study showed enhanced Runx2 and osteocalcin expression, as well as increased alkaline phosphatase activity and calcium deposition, thus demonstrating a further enhanced therapeutic potential of a biomaterial previously optimised for bone repair applications. The promising features of this platform offer potential for a myriad of applications beyond bone repair and tissue engineering, thus presenting a new paradigm for microRNA-based therapeutics.

Funding

BioAT. European Regional Development Fund. European Research Council

History

Comments

The original article is available at www.nature.com

Published Citation

Mencía Castaño I, Curtin CM, Duffy GP1, O'Brien FJ. Next generation bone tissue engineering: non-viral miR-133a inhibition using collagen-nanohydroxyapatite scaffolds rapidly enhances osteogenesis. Scientific Reports. 2016;6:27941

Publication Date

14/06/2016

Publisher

Nature Publishing Group

PubMed ID

27297802

Exports

Logo branding

Categories

Exports